At the current price, it is trading around the support line which is 0.40 to 0.405. it will be good to get it at 40 to 40.5 cts. FA wise they are making profit and they more into medical spec. will type out more on this counter tonight. Just give u guys a brief info. Don miss this boat again. :)
Chances of it going lower than 40 cts is slim. the next supporting line we will be looking at is 0.375.
Today at closing, it closed at 40.5 cts. Maybe a reserve in trend is coming up. Good Luck for those who had invested in this. You will see it grow in the mid to long term period.
Some news that I had cut out from DJ Market talk.
Pequot Healthcare Emerging Market Master Fund Ltd has increased its stack to 9.01% as of May 24, 2007.
-------------------------------------------
DJ MARKET TALK: Pacific Healthcare +3%; CIMB Lifts Target
0823 GMT [Dow Jones] Pacific Healthcare (P47.SG) +3% at 34.5 Singapore cents in active trade on S$32 million 40:60 JV with Kuwait Finance House to set up medical centers in Asia, modeled after company's Singapore operations. CIMB ups target price to 51 cents from 45 cents, keeps Outperform call. Says stock has been lagging peers over past year on lack of appreciation for its business model, niche aesthetic healthcare presence. Adds company in stronger financial position to offer services in China, India, Vietnam given recent sale of assets for S$38 million, placement of shares to raise S$12 million. Resistance at 36 cents (Feb. 13 intraday high). (FKH)
Contact us in Singapore. 65 64154 150;
MarketTalk@dowjones.com
(END) Dow Jones Newswires
February 15, 2007 03:23 ET (08:23 GMT)
-----------------------------------
In Singapore alone its 92 healthcare professional is its most valuable asset, as there’s an inflow of patients coming into spore to seek specialist treatment. Even its rival raffles medical group has garnered interest from Temasek who is now trading at 42 P/E compared to Pac HC P/E of 24, which is relatively low in this type of industry.
With the government trying to develop spore into a medical hub with more research centers and more involvement in expanding the services, we should see a lot of support from the government for this sector.
Recently it formed a JV with Kuwait finance house, moving into Middle East, one of the 3 largest markets I would presume after China and India who is in need of the specialist platform. The JV will establish more new medical centers in the ME region modeled after their spore operations.
It is also moving into Vietnam as it clinched a 25million contract to design; build and management contract in Vietnam. The amount is not the issue but rather the group’s direction. It is aggressively moving into countries like China, ME, India and Vietnam, who are in need of their expertise. With their presence in all these countries, I am expecting a re rating of the stock somewhere after the annual report. It is a good long-term counter, though it would be good to see come consolidation ard 0.40 or so.